Loading...

PledPharma

DB:P0F
Snowflake Description

Exceptional growth potential with flawless balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
P0F
DB
SEK959M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

PledPharma AB, a pharmaceutical company, develops pharmaceuticals for debilitating and life-threatening medical conditions. The last earnings update was 98 days ago. More info.


Add to Portfolio Compare Print
P0F Share Price and Events
7 Day Returns
-4.7%
DB:P0F
-2.7%
DE Biotechs
1.5%
DE Market
1 Year Returns
-
DB:P0F
-10.6%
DE Biotechs
-6.2%
DE Market
P0F Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
PledPharma (P0F) -4.7% 1.4% - - - -
DE Biotechs -2.7% 3.8% -8.5% -10.6% 47.4% 10.3%
DE Market 1.5% 6% 8.5% -6.2% 10.7% 15.3%
1 Year Return vs Industry and Market
  • No trading data on P0F.
  • No trading data on P0F.
Price Volatility
P0F
Industry
5yr Volatility vs Market

Value

 Is PledPharma undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of PledPharma to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for PledPharma.

DB:P0F Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 2 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 8%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:P0F
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.45
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.449 (1 + (1- 22%) (0%))
1.301
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.3
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (1.301 * 5.96%)
7.98%

Discounted Cash Flow Calculation for DB:P0F using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for PledPharma is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:P0F DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (SEK, Millions) Source Present Value
Discounted (@ 7.98%)
2019 -88.00 Analyst x1 -81.50
2020 -96.50 Analyst x2 -82.76
2021 49.00 Analyst x1 38.92
2022 65.61 Est @ 33.9% 48.26
2023 81.23 Est @ 23.8% 55.33
2024 94.81 Est @ 16.73% 59.81
2025 105.98 Est @ 11.78% 61.92
2026 114.79 Est @ 8.31% 62.11
2027 121.55 Est @ 5.89% 60.90
2028 126.64 Est @ 4.19% 58.76
Present value of next 10 years cash flows SEK281.75
DB:P0F DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= SEK126.64 × (1 + 0.23%) ÷ (7.98% – 0.23%)
SEK1,637.19
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= SEK1,637.19 ÷ (1 + 7.98%)10
SEK759.67
DB:P0F Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= SEK281.75 + SEK759.67
SEK1,041.42
Equity Value per Share
(SEK)
= Total value / Shares Outstanding
= SEK1,041.42 / 48.67
SEK21.4
DB:P0F Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:P0F represents 0.09289x of OM:PLED
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.09289x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (SEK) x Listing Adjustment Factor
= SEK 21.40 x 0.09289
€1.99
Value per share (EUR) From above. €1.99
Current discount Discount to share price of €1.83
= -1 x (€1.83 - €1.99) / €1.99
7.9%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price PledPharma is available for.
Intrinsic value
8%
Share price is €1.83 vs Future cash flow value of €1.99
Current Discount Checks
For PledPharma to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • PledPharma's share price is below the future cash flow value, but not at a moderate discount (< 20%).
  • PledPharma's share price is below the future cash flow value, but not at a substantial discount (< 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for PledPharma's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are PledPharma's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:P0F PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in SEK SEK-1.75
OM:PLED Share Price ** OM (2019-04-23) in SEK SEK19.7
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.44x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 19.6x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of PledPharma.

DB:P0F PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= OM:PLED Share Price ÷ EPS (both in SEK)

= 19.7 ÷ -1.75

-11.28x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • PledPharma is loss making, we can't compare its value to the Europe Biotechs industry average.
  • PledPharma is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does PledPharma's expected growth come at a high price?
Raw Data
DB:P0F PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -11.28x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts
34.5%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 269 Publicly-Listed Companies 1.56x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for PledPharma, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on PledPharma's assets?
Raw Data
DB:P0F PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in SEK SEK4.51
OM:PLED Share Price * OM (2019-04-23) in SEK SEK19.7
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.71x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.84x
DB:P0F PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= OM:PLED Share Price ÷ Book Value per Share (both in SEK)

= 19.7 ÷ 4.51

4.37x

* Primary Listing of PledPharma.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • PledPharma is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess PledPharma's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. PledPharma has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is PledPharma expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
34.5%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is PledPharma expected to grow at an attractive rate?
  • PledPharma's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • PledPharma's earnings growth is expected to exceed the Germany market average.
  • PledPharma's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:P0F Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:P0F Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts 34.5%
DB:P0F Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 2 Analysts 51.7%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:P0F Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
All numbers in SEK Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:P0F Future Estimates Data
Date (Data in SEK Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2021-12-31 141 49 46 2
2020-12-31 31 -97 -98 2
2019-12-31 49 -88 -91 1
DB:P0F Past Financials Data
Date (Data in SEK Millions) Revenue Cash Flow Net Income *
2018-12-31 28 -80 -85
2018-09-30 31 -105 -95
2018-06-30 24 -97 -103
2018-03-31 14 -90 -91
2017-12-31 14 -87 -88
2017-09-30 -51 -67
2017-06-30 0 -49 -48
2017-03-31 -41 -44
2016-12-31 -36 -38
2016-09-30 -36 -36
2016-06-30 -38 -39
2016-03-31 -44 -39

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • PledPharma's earnings are expected to grow significantly at over 20% yearly.
  • PledPharma's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:P0F Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below

All data from PledPharma Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:P0F Future Estimates Data
Date (Data in SEK Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2021-12-31 0.94 0.94 0.94 1.00
2020-12-31 -2.01 -1.50 -2.52 2.00
2019-12-31 -1.87 -1.87 -1.87 1.00
DB:P0F Past Financials Data
Date (Data in SEK Millions) EPS *
2018-12-31 -1.75
2018-09-30 -1.95
2018-06-30 -2.13
2018-03-31 -1.88
2017-12-31 -1.81
2017-09-30 -1.50
2017-06-30 -1.20
2017-03-31 -1.25
2016-12-31 -1.29
2016-09-30 -1.25
2016-06-30 -1.38
2016-03-31 -1.36

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • PledPharma is expected to efficiently use shareholders’ funds in the future (Return on Equity greater than 20%).
X
Future performance checks
We assess PledPharma's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
PledPharma has a total score of 6/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has PledPharma performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare PledPharma's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • PledPharma does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare PledPharma's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare PledPharma's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
PledPharma's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from PledPharma Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:P0F Past Revenue, Cash Flow and Net Income Data
Date (Data in SEK Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 28.21 -85.00 31.36
2018-09-30 30.70 -94.99 32.98
2018-06-30 23.78 -103.49 32.75
2018-03-31 14.31 -91.47 29.63
2017-12-31 13.58 -87.94 26.52
2017-09-30 -67.27 21.21
2017-06-30 0.20 -47.86 18.89
2017-03-31 -43.66 19.14
2016-12-31 -38.22 19.52
2016-09-30 -35.56 19.28
2016-06-30 -39.06 18.97
2016-03-31 -38.52 18.45
2015-12-31 -43.84 18.18
2015-09-30 -52.75 28.31
2015-06-30 -52.58 26.04
2015-03-31 -53.81 18.88
2014-12-31 -48.42 19.36
2014-09-30 -37.68 5.86
2014-06-30 -30.92 5.58
2014-03-31 -24.29 9.69
2013-12-31 -25.55 6.03
2013-09-30 -26.98 16.03
2013-06-30 -28.11 16.33
2013-03-31 -32.61 17.28
2012-12-31 -33.86 17.38
2012-09-30 0.00 -50.89 16.58
2012-06-30 5.24 -47.74 16.65

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if PledPharma has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if PledPharma has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if PledPharma improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess PledPharma's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
PledPharma has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is PledPharma's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up PledPharma's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • PledPharma is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • PledPharma has no long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of PledPharma's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • PledPharma has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from PledPharma Company Filings, last reported 3 months ago.

DB:P0F Past Debt and Equity Data
Date (Data in SEK Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 219.36 0.00 229.88
2018-09-30 241.50 0.00 250.27
2018-06-30 259.69 0.00 267.05
2018-03-31 287.90 0.00 294.34
2017-12-31 303.71 0.00 309.53
2017-09-30 335.27 0.00 354.34
2017-06-30 362.42 0.00 363.75
2017-03-31 377.28 0.00 382.04
2016-12-31 389.56 0.00 394.00
2016-09-30 21.27 0.00 23.59
2016-06-30 29.20 0.00 31.67
2016-03-31 41.19 0.00 43.68
2015-12-31 48.03 0.00 50.36
2015-09-30 56.84 0.00 59.31
2015-06-30 68.27 0.00 69.59
2015-03-31 78.51 0.00 86.07
2014-12-31 90.66 0.00 100.30
2014-09-30 36.42 0.00 40.68
2014-06-30 47.69 0.00 47.80
2014-03-31 40.18 0.00 41.39
2013-12-31 46.95 0.00 49.30
2013-09-30 53.91 0.00 54.91
2013-06-30 58.42 0.00 59.12
2013-03-31 45.91 0.00 48.26
2012-12-31 53.94 0.00 58.81
2012-09-30 62.06 0.00 65.49
2012-06-30 67.71 0.00 68.61
  • PledPharma has no debt.
  • PledPharma has not taken on any debt in the past 5 years.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • PledPharma has sufficient cash runway for 2.9 years based on current free cash flow.
  • PledPharma has sufficient cash runway for 2.3 years if free cash flow continues to grow at historical rates of 35.2% each year.
X
Financial health checks
We assess PledPharma's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. PledPharma has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is PledPharma's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from PledPharma dividends. Estimated to be 0% next year.
If you bought €2,000 of PledPharma shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate PledPharma's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate PledPharma's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:P0F Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:P0F Future Dividends Estimate Data
Date (Data in SEK) Dividend per Share (annual) Avg. No. Analysts
2021-12-31 0.00 1.00
2020-12-31 0.00 1.00
2019-12-31 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as PledPharma has not reported any payouts.
  • Unable to verify if PledPharma's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of PledPharma's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as PledPharma has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of PledPharma's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess PledPharma's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can PledPharma afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. PledPharma has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of PledPharma's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Nicklas Westerholm
COMPENSATION SEK1,499,000
AGE 42
TENURE AS CEO 1.8 years
CEO Bio

Mr. Nicklas Westerholm has been the Chief Executive Officer of PledPharma AB since June 16, 2017. Mr. Westerholm has been working in the AstraZeneca Group since 1995 in several global roles and different business areas, served as it's Vice President Project & Portfolio Management, Cardiovascular and Metabolic Diseases, Global Medicines Development Unit. He also served as an Executive Officer, Vice President of Japan Operations, Director of Investor Relations, Head of Global API Supply and Head of Development Manufacture at AstraZeneca Group. Mr. Westerholm has studied analytical and organic chemistry at Stockholm University and Chemical Engineering at KTH Royal Institute of Technology. He has also participated in educational programs at the University of Warwick, INSEAD and Harvard Business School.

CEO Compensation
  • Insufficient data for Nicklas to compare compensation growth.
  • Nicklas's remuneration is lower than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the PledPharma management team in years:

13.3
Average Tenure
58.5
Average Age
  • The average tenure for the PledPharma management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Nicklas Westerholm

TITLE
Chief Executive Officer
COMPENSATION
SEK1M
AGE
42
TENURE
1.8 yrs

Jacques Näsström

TITLE
VP of Preclinical R&D and CSO
COMPENSATION
SEK655K
AGE
59

Torsten Almén

TITLE
TENURE
13.3 yrs

Ingemar Lundström

TITLE
AGE
75
TENURE
13.3 yrs

Lou Ignarro

TITLE
AGE
76
TENURE
13.3 yrs

Heidi Brurok

TITLE
TENURE
13.3 yrs

Rob Towart

TITLE
TENURE
13.3 yrs

Yilmaz Mahshid

TITLE
Chief Financial Officer
AGE
39
TENURE
1.3 yrs

Stefan Carlsson

TITLE
Chief Medical Officer & VP of Clinical Development
AGE
58
TENURE
1.4 yrs
Board of Directors Tenure

Average tenure and age of the PledPharma board of directors in years:

1.8
Average Tenure
57
Average Age
  • The average tenure for the PledPharma board of directors is less than 3 years, this suggests a new board.
Board of Directors

Håkan Åström

TITLE
Chairman
COMPENSATION
SEK550K
AGE
71
TENURE
8.3 yrs

Sten Nilsson

TITLE
Director
COMPENSATION
SEK280K
AGE
70
TENURE
6.3 yrs

Gunilla Osswald

TITLE
Director
COMPENSATION
SEK175K
AGE
57
TENURE
2.3 yrs

Elisabeth Svanberg

TITLE
Director
COMPENSATION
SEK175K
AGE
57
TENURE
2.3 yrs

Marie Trägårdh

TITLE
Director
COMPENSATION
SEK150K
AGE
57
TENURE
2 yrs

Guido Cavaletti

TITLE
Member of Scientific Advisory Board
TENURE
1.7 yrs

David Cella

TITLE
Member of Scientific Advisory Board
TENURE
1.7 yrs

Bengt Glimelius

TITLE
Member of Scientific Advisory Board
TENURE
1.7 yrs

Rolf Karlsten

TITLE
Member of Scientific Advisory Board
TENURE
1.7 yrs

Laura James

TITLE
Member of Scientific Advisory Board
TENURE
0.8 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess PledPharma's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. PledPharma has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

PledPharma AB, a pharmaceutical company, develops pharmaceuticals for debilitating and life-threatening medical conditions. It develops PledOx, which is in Phase IIb clinical trial to reduce side effects in the treatment of colorectal cancer with the chemotherapy FOLFOX; and Aladote for the treatment of acute liver failure caused by acetaminophen/paracetamol poisoning. The company was founded in 2006 and is based in Stockholm, Sweden. PledPharma AB is a subsidiary of Accelerator Nordic AB.

Details
Name: PledPharma AB
P0F
Exchange: DB
Founded: 2006
SEK91,263,308
48,666,656
Website: http://pledpharma.se
Address: PledPharma AB
Grev Turegatan 11 C,
Stockholm,
Stockholm County, 114 46,
Sweden
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
OM PLED Share Capital OMX Nordic Exchange Stockholm SE SEK 07. Apr 2011
DB P0F Share Capital Deutsche Boerse AG DE EUR 07. Apr 2011
BST P0F Share Capital Boerse-Stuttgart DE EUR 07. Apr 2011
Number of employees
Current staff
Staff numbers
8
PledPharma employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/23 22:43
End of day share price update: 2019/04/23 00:00
Last estimates confirmation: 2019/04/08
Last earnings filing: 2019/01/15
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.